CheckMate 141: What the Head and Neck Cancer Trial Found

A situation with almost nothing to offer

Squamous-cell head and neck cancer that comes back within six months of platinum chemotherapy has an outlook measured in months. When CheckMate 141 opened, the options after that point were few and none of them had been shown to extend life.

That is the setting to keep in mind while reading the numbers. A gain of a couple of months here is not the same kind of finding as a gain of a couple of months in a disease with a long horizon.

What the control arm actually was

Field	Detail
Trial	CheckMate 141
Identifier	NCT02105636
Phase	Phase 3
Design	Randomised 2:1, open-label
Cancer type	Recurrent squamous-cell head and neck cancer progressing within six months of platinum chemotherapy
Comparator	Nivolumab by infusion every two weeks, against single-agent standard therapy
Primary endpoint	Overall survival

361 people were randomised, two to nivolumab for every one to the control arm. The control was not a single drug. Each investigator chose between methotrexate, docetaxel and cetuximab — three treatments that work in different ways and are given on different schedules.

That is a realistic comparison, because it reflects what a clinic would actually do. It is also a messier one, because "standard therapy" here is really three arms folded into one.

The survival result

Median survival was 7.5 months with nivolumab (95% CI 5.5 to 9.1) and 5.1 months with standard therapy (95% CI 4.0 to 6.0). The hazard ratio for death was 0.70 (97.73% CI 0.51 to 0.96, p=0.01).

The medians differ by 2.4 months. The one-year figures differ by more: 36.0% of the nivolumab group were alive at a year, against 16.6%. That is roughly 19 percentage points.

That shape — a modest shift in the middle, a bigger one in the tail — is what a drug looks like when it helps a minority a great deal rather than helping everyone a little.

The endpoint that did not move

Median progression-free survival was 2.0 months with nivolumab (95% CI 1.9 to 2.1) and 2.3 months with standard therapy (95% CI 1.9 to 3.1). The hazard ratio was 0.89 (95% CI 0.70 to 1.13) with a p-value of 0.32. On that measure, nivolumab was not better.

At six months the picture flips: 19.7% were progression-free on nivolumab against 9.9%. Tumours shrank in 13.3% against 5.8%.

An early scan, in other words, was a poor guide to who was benefiting from this drug.

Fewer severe side effects, and steadier quality of life

Serious treatment-related side effects — grade 3 or 4 — occurred in 13.1% of the nivolumab group and 35.1% of the standard-therapy group.

Physical, role and social functioning stayed stable in the nivolumab group over the trial. In the standard-therapy group they got meaningfully worse. For a cancer that affects speaking, swallowing and appearance, that is not a footnote.

What this trial cannot tell you

• Which of the three control drugs nivolumab is better than. They were pooled, so the trial cannot rank them individually.
• Whether the average patient gains 2.4 months. The medians say that; the one-year rates suggest the gain is concentrated in a minority.
• Whether an early scan should guide the decision to stop. Progression-free survival did not favour nivolumab, yet survival did.
• Anything about first treatment. Everyone here had already had platinum chemotherapy and progressed quickly on it.

Questions if head and neck cancer has come back

• How soon after platinum chemotherapy did this come back, and does that fit this trial?
• If the first scan looks worse, how will you decide whether to continue?
• What would each option mean for swallowing, speech and eating?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• NEJM: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141) (primary)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.